292 related articles for article (PubMed ID: 21412389)
1. Dyslipidemia related to antiretroviral therapy.
Estrada V; Portilla J
AIDS Rev; 2011; 13(1):49-56. PubMed ID: 21412389
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral therapy with heart.
Randell P; Moyle G
Am J Ther; 2009; 16(6):579-84. PubMed ID: 19940610
[TBL] [Abstract][Full Text] [Related]
3. High-risk dysmetabolism disorders associated with HAART-treated HIV disease, and reimbursement of lipid-lowering drugs, in a clinical and a socio-economic perspective.
Manfredi R
AIDS Rev; 2005; 7(3):155-60. PubMed ID: 16302463
[TBL] [Abstract][Full Text] [Related]
4. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
6. Therapy insight: Body-shape changes and metabolic complications associated with HIV and highly active antiretroviral therapy.
Falutz J
Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):651-61. PubMed ID: 17710086
[TBL] [Abstract][Full Text] [Related]
7. Management of metabolic complications and cardiovascular risk in HIV-infected patients.
Blanco F; San Román J; Vispo E; López M; Salto A; Abad V; Soriano V
AIDS Rev; 2010; 12(4):231-41. PubMed ID: 21179187
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. HIV-associated dyslipidaemia among HIV antibody-positive patients in Ireland: prevalence and management strategies.
Nolan DP; O'Connor MB; O'Connor C; Moriarty M; O'Leary A; Bergin C
Int J STD AIDS; 2010 Jan; 21(1):75-6. PubMed ID: 19884356
[No Abstract] [Full Text] [Related]
10. A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Bain AM; White EA; Rutherford WS; Rahman AP; Busti AJ
Pharmacotherapy; 2008 Jul; 28(7):932-8. PubMed ID: 18576908
[TBL] [Abstract][Full Text] [Related]
11. [Lipodystrophy syndrome in HIV-infected patients. Clinical and diagnostic features].
Streinu-Cercel A; Ion DA; Chivu LI; Chivu RD
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):521-5. PubMed ID: 17571539
[TBL] [Abstract][Full Text] [Related]
12. Improvement of dyslipidemia during different HAART regimens: tenofovir- versus stavudine-containing antiretroviral combinations.
Manfredi R
Clin Infect Dis; 2006 May; 42(9):1345-7; author reply 1347-8. PubMed ID: 16586399
[No Abstract] [Full Text] [Related]
13. [Coronary heart disease associated with the use of highly active antiretroviral therapy (HAART). A case report and review].
Neumann T; Kondratieva J; Eggebrecht H; Wieneke H; Esser S; Bartel T; Erbel R
Herz; 2005 Sep; 30(6):504-9. PubMed ID: 16170681
[TBL] [Abstract][Full Text] [Related]
14. Treating antiretroviral-induced dyslipidemia in HIV-infected adults.
Scordo KA
Nurse Pract; 2010 Jul; 35(7):32-7; quiz 37-8. PubMed ID: 20555242
[No Abstract] [Full Text] [Related]
15. Clinical management considerations for dyslipidemia in HIV-infected individuals.
Kirchner JT
Postgrad Med; 2012 Jan; 124(1):31-40. PubMed ID: 22314112
[TBL] [Abstract][Full Text] [Related]
16. Lipid metabolism in treated HIV Infection.
Dubé MP; Cadden JJ
Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
[TBL] [Abstract][Full Text] [Related]
17. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Llibre JM; Domingo P; Palacios R; Santos J; Pérez-Elías MJ; Sánchez-de la Rosa R; Miralles C; Antela A; Moreno S;
AIDS; 2006 Jun; 20(10):1407-14. PubMed ID: 16791015
[TBL] [Abstract][Full Text] [Related]
18. Management of dyslipidemia and other cardiovascular risk factors in HIV-infected patients: case-based review.
Aberg JA
Top HIV Med; 2006; 14(4):134-9. PubMed ID: 17114827
[TBL] [Abstract][Full Text] [Related]
19. HIV-associated and antiretroviral-induced hyperlipidaemia: an update.
Mauss S
J HIV Ther; 2003 May; 8(2):29-31. PubMed ID: 12838161
[TBL] [Abstract][Full Text] [Related]
20. The nurse practitioner's role in managing dyslipidemia and other cardiovascular risk factors in HIV-infected patients: impact of antiretroviral therapy.
Willard S
J Assoc Nurses AIDS Care; 2006; 17(1):7-17. PubMed ID: 16686080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
